Fort Sheridan Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 78,522 shares of the biopharmaceutical company’s stock after acquiring an additional 1,730 shares during the period. Pfizer accounts for about 1.3% of Fort Sheridan Advisors LLC’s portfolio, making the stock its 13th biggest position. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $4,637,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in the company. Ibex Wealth Advisors bought a new position in Pfizer in the 3rd quarter valued at about $26,000. Econ Financial Services Corp bought a new position in Pfizer in the 4th quarter valued at about $31,000. PYA Waltman Capital LLC bought a new position in Pfizer in the 4th quarter valued at about $31,000. TFO TDC LLC lifted its position in Pfizer by 126.9% in the 4th quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 373 shares in the last quarter. Finally, MFA Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter valued at about $38,000. 66.50% of the stock is currently owned by institutional investors.
In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.05% of the stock is owned by company insiders.
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.80 by ($0.18). Pfizer had a net margin of 26.97% and a return on equity of 39.33%. The business had revenue of $25.66 billion during the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the prior year, the firm posted $0.93 earnings per share. The firm’s quarterly revenue was up 76.8% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 6.69 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.21%. The ex-dividend date of this dividend is Thursday, May 12th. Pfizer’s payout ratio is 36.70%.
Several equities analysts recently weighed in on PFE shares. Mizuho dropped their price target on shares of Pfizer from $56.00 to $55.00 in a research report on Thursday, February 10th. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research report on Tuesday, May 3rd. BMO Capital Markets lifted their target price on shares of Pfizer from $60.00 to $76.00 in a research report on Friday, January 14th. Wells Fargo & Company dropped their target price on shares of Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Finally, Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 target price on the stock. in a research report on Tuesday, February 15th. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $57.05.
Pfizer Company Profile (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.